329 related articles for article (PubMed ID: 12702579)
1. Inactivation of RAS association domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection.
Kuzmin I; Liu L; Dammann R; Geil L; Stanbridge EJ; Wilczynski SP; Lerman MI; Pfeifer GP
Cancer Res; 2003 Apr; 63(8):1888-93. PubMed ID: 12702579
[TBL] [Abstract][Full Text] [Related]
2. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
[TBL] [Abstract][Full Text] [Related]
3. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma.
Byun DS; Lee MG; Chae KS; Ryu BG; Chi SG
Cancer Res; 2001 Oct; 61(19):7034-8. PubMed ID: 11585730
[TBL] [Abstract][Full Text] [Related]
4. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma.
Dammann R; Schagdarsurengin U; Liu L; Otto N; Gimm O; Dralle H; Boehm BO; Pfeifer GP; Hoang-Vu C
Oncogene; 2003 Jun; 22(24):3806-12. PubMed ID: 12802288
[TBL] [Abstract][Full Text] [Related]
5. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers.
Dammann R; Yang G; Pfeifer GP
Cancer Res; 2001 Apr; 61(7):3105-9. PubMed ID: 11306494
[TBL] [Abstract][Full Text] [Related]
6. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
7. Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma.
Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
Clin Cancer Res; 2003 Apr; 9(4):1441-5. PubMed ID: 12684417
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
[TBL] [Abstract][Full Text] [Related]
9. Frequent hypermethylation of the RASSF1A gene in prostate cancer.
Liu L; Yoon JH; Dammann R; Pfeifer GP
Oncogene; 2002 Oct; 21(44):6835-40. PubMed ID: 12360410
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
[TBL] [Abstract][Full Text] [Related]
11. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines.
Harada K; Toyooka S; Maitra A; Maruyama R; Toyooka KO; Timmons CF; Tomlinson GE; Mastrangelo D; Hay RJ; Minna JD; Gazdar AF
Oncogene; 2002 Jun; 21(27):4345-9. PubMed ID: 12082624
[TBL] [Abstract][Full Text] [Related]
12. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix.
Cohen Y; Singer G; Lavie O; Dong SM; Beller U; Sidransky D
Clin Cancer Res; 2003 Aug; 9(8):2981-4. PubMed ID: 12912945
[TBL] [Abstract][Full Text] [Related]
13. RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1.
Tommasi S; Dammann R; Jin SG; Zhang XF; Avruch J; Pfeifer GP
Oncogene; 2002 Apr; 21(17):2713-20. PubMed ID: 11965544
[TBL] [Abstract][Full Text] [Related]
14. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
[TBL] [Abstract][Full Text] [Related]
15. Methylation of the RASSF1A gene in human cancers.
Pfeifer GP; Yoon JH; Liu L; Tommasi S; Wilczynski SP; Dammann R
Biol Chem; 2002 Jun; 383(6):907-14. PubMed ID: 12222680
[TBL] [Abstract][Full Text] [Related]
16. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.
Yang Q; Zage P; Kagan D; Tian Y; Seshadri R; Salwen HR; Liu S; Chlenski A; Cohn SL
Clin Cancer Res; 2004 Dec; 10(24):8493-500. PubMed ID: 15623630
[TBL] [Abstract][Full Text] [Related]
17. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells.
Kuzmin I; Gillespie JW; Protopopov A; Geil L; Dreijerink K; Yang Y; Vocke CD; Duh FM; Zabarovsky E; Minna JD; Rhim JS; Emmert-Buck MR; Linehan WM; Lerman MI
Cancer Res; 2002 Jun; 62(12):3498-502. PubMed ID: 12067994
[TBL] [Abstract][Full Text] [Related]
18. Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis.
Overmeer RM; Henken FE; Bierkens M; Wilting SM; Timmerman I; Meijer CJ; Snijders PJ; Steenbergen RD
J Pathol; 2009 Nov; 219(3):327-36. PubMed ID: 19662663
[TBL] [Abstract][Full Text] [Related]
19. "Low-risk" and "high-risk" HPV-infection and K-ras gene point mutations in human cervical cancer: a study of 31 cases.
Stenzel A; Semczuk A; Rózyńskal K; Jakowicki J; Wojcierowski J
Pathol Res Pract; 2001; 197(9):597-603. PubMed ID: 11569923
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.
Agathanggelou A; Dallol A; Zöchbauer-Müller S; Morrissey C; Honorio S; Hesson L; Martinsson T; Fong KM; Kuo MJ; Yuen PW; Maher ER; Minna JD; Latif F
Oncogene; 2003 Mar; 22(10):1580-8. PubMed ID: 12629521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
